BIOGEN INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
BIOGEN INC. (BIIB) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements of $149.30 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements · last filed 2025-10-30
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2025-09-30 was $149.30M.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2024-09-30 was $0.00.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2014-12-31 was -$100.00K.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2014-09-30 was -$900.00K.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2014 was -$5.50M.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2013 was -$3.30M.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2012 was $0.00.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2010 was $1.10M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 12 month |
|---|---|---|---|---|
| 2025-09-30 | $149.30M 10-Q · filed 2025-10-30 | $150.00M 10-Q · filed 2025-10-30 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | ||
| 2014-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | -$1.00M derived: sum of 2 quarters · filed 2015-02-04 | -$5.50M derived: sum of 3 quarters · filed 2015-02-04 | -$5.50M 10-K · filed 2015-02-04 |
| 2014-09-30 | -$900.00K 10-Q · filed 2014-10-22 | -$5.40M derived: sum of 2 quarters · filed 2014-10-22 | -$5.40M 10-Q · filed 2014-10-22 | -$7.20M derived: sum of 4 quarters · filed 2015-02-04 |
| 2014-06-30 | -$4.50M 10-Q · filed 2014-07-23 | -$4.50M 10-Q · filed 2014-07-23 | -$6.30M derived: sum of 3 quarters · filed 2015-02-04 | -$6.30M derived: sum of 4 quarters · filed 2015-02-04 |
| 2014-03-31 | $0.00 10-Q · filed 2014-04-23 | -$1.80M derived: sum of 2 quarters · filed 2015-02-04 | -$1.80M derived: sum of 3 quarters · filed 2015-02-04 | -$1.80M derived: sum of 4 quarters · filed 2015-02-04 |
| 2013-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | -$1.80M derived: sum of 2 quarters · filed 2015-02-04 | -$1.80M derived: sum of 3 quarters · filed 2015-02-04 | -$3.30M 10-K · filed 2015-02-04 |
| 2013-09-30 | $0.00 10-Q · filed 2014-10-22 | $0.00 derived: sum of 2 quarters · filed 2014-10-22 | -$1.50M 10-Q · filed 2014-10-22 | -$1.50M derived: sum of 4 quarters · filed 2014-10-22 |
| 2013-06-30 | $0.00 10-Q · filed 2014-07-23 | -$1.50M 10-Q · filed 2014-07-23 | -$1.50M derived: sum of 3 quarters · filed 2014-07-23 | -$1.50M derived: sum of 4 quarters · filed 2014-07-23 |
| 2013-03-31 | -$1.50M 10-Q · filed 2014-04-23 | -$1.50M derived: sum of 2 quarters · filed 2014-04-23 | -$1.50M derived: sum of 3 quarters · filed 2014-04-23 | -$1.50M derived: sum of 4 quarters · filed 2014-04-23 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $0.00 derived: sum of 2 quarters · filed 2014-02-06 | $0.00 derived: sum of 3 quarters · filed 2014-02-06 | $0.00 10-K · filed 2014-02-06 |
| 2012-09-30 | $0.00 10-Q · filed 2013-10-28 | $0.00 derived: sum of 2 quarters · filed 2013-10-28 | $0.00 10-Q · filed 2013-10-28 | |
| 2012-06-30 | $0.00 10-Q · filed 2013-07-25 | $0.00 10-Q · filed 2013-07-25 | ||
| 2012-03-31 | $0.00 10-Q · filed 2013-04-25 | |||
| 2011-06-30 | $0.00 10-Q · filed 2011-07-26 | $0.00 10-Q · filed 2011-07-26 | ||
| 2010-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $1.10M derived: sum of 2 quarters · filed 2012-02-03 | $1.10M 10-K · filed 2012-02-03 | |
| 2010-09-30 | $600.00K 10-Q · filed 2011-10-28 | $600.00K 10-Q · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |